Complete Remission of Liver and Bone Metastases After Nivolumab Treatment in a Patient with Renal Cell Carcinoma: The Potential Implication of MLH1 Mutations
- *Corresponding Author:
- Jue Wang
University of Arizona Cancer
Center at St. Joseph’s Hospital and
Medical Center 625 N. 6th St. Phoenix
AZ 85004, USA
E-mail: [email protected]
Received Date: December 03, 2016 Accepted Date: February 21, 2017 Published Date: February 26, 2017
Citation: Marsh S, Wang J (2017) Complete Remission of Liver and Bone Metastases After Nivolumab Treatment in a Patient with Renal Cell Carcinoma: The Potential Implication of MLH1 Mutations. Oncol Cancer Case Rep 3: 125. doi: 10.4172/2471- 8556.1000125
Copyright: © 2017 Marsh S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
We report a case of complete remission of liver metastasis and near complete remission of bone metastases with nivolumab treatment in a mRCC patient, and discuss the potential implication of MLH1 mutations in this extraordinary response.